Trial Profile
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2022
Price :
$35
*
At a glance
- Drugs Tislelizumab (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Therapeutic Use
- Sponsors BeiGene
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 25 Mar 2022 Number of treatment arms have been increased from 1 to 3 by the addition of separate experimental cohort arms as- Cohort 1: ENKTL, Cohort 2: PTCL-NOS, AITL, and ALCL and Cohort 3: MF and SS.